Company: INDP
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001493152-25-021759
Chunk: 54

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 8
Chunk 54
---
 
     (94,764) 
     (303,201)
  
    Change in fair value of convertible promissory notes 
     365,718  
     -  
     1,153,421  
     - 
  
    Net loss 
    $2,975,117  
    $3,069,036  
    $12,736,466  
    $10,890,980 

NOTE
10: SUBSEQUENT EVENTS

The
Company evaluated subsequent events from September 30, 2025, the date of these unaudited condensed consolidated financial statements,
through November 12, 2025, which represents the date the condensed consolidated financial statements were issued, for events requiring
recognition or disclosure in the condensed consolidated financial statements for the nine months ended September 30, 2025. The Company
concluded that no events have occurred that would require recognition or disclosure in the condensed consolidated financial statements.

F-12

Item
2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Unless
the context indicates otherwise, in this Quarterly Report, the terms “Indaptus,” “the Company,” “we,”
“us” and “our” refer to Indaptus Therapeutics, Inc. (formerly Intec Parent, Inc., the successor of Intec Pharma
Ltd. following the domestication merger) and, where appropriate, its consolidated subsidiaries following the domestication merger and
the reverse merger described in our previous periodic reports. References to “Intec Israel” refer to Intec Pharma Ltd., the
predecessor of Indaptus prior to the domestication merger, and references to “Decoy” refer to Decoy Biosystems, Inc., the
entity acquired by Indaptus in connection with the reverse merger.

You
should read the following discussion and analysis of our financial condition and results of operations along with our consolidated financial
statements and the related notes and other financial information included elsewhere in this Quarterly Report and our Annual Report on
Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission (“SEC”) on March 13, 2025
(the “2024 Annual Report on Form 10-K”). The following discussion contains forward-looking statements that are subject to
risks, uncertainties and assumptions. You should review the sections titled “Summary Risk Factors” and Part II. Item 1A.
Risk Factors in this Quarterly Report for